News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

FDA Approves Zometa for Cancer-Related Bone Complications

Apr 1, 2002
Oncology NEWS InternationalOncology NEWS International Vol 11 No 4
Volume 11
Issue 4

EAST HANOVER, New Jersey-The US Food and Drug Administration has approved the Novartis drug Zometa (zoledronic acid for injection) for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy.

EAST HANOVER, New Jersey—The US Food and Drug Administration has approved the Novartis drug Zometa (zoledronic acid for injection) for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy.

These solid tumors include prostate cancer, lung cancer, breast cancer, and other solid tumor types. In prostate cancer, patients should have progressed after treatment with at least one hormonal therapy.

The trials that led to the approval mark the first time any bisphosphonate has shown efficacy in treating bone complications in patients with prostate cancer, lung cancer, and other solid tumors, Novartis said in a news release. Further, Zometa offers patients, nurses, and clinicians a convenient 4 mg, 15-minute infusion time.

Novartis submitted the new drug application (NDA) for the bone metastases indication to the FDA in August 2001, and in October 2001, the NDA received a priority review designation. Zometa was previously approved for the treatment of hypercalemia of malignancy.

The approval is based on data from three large international clinical trials evaluating more than 3,000 patients with prostate, lung, and breast cancer, and other solid tumors, and multiple myeloma. In two placebo-controlled studies in patients with bone metastases from prostate cancer or other solid tumors, both the number of patients with skeletal events and the time to first skeletal-related event were decreased, compared with placebo.

Articles in this issue

Infection Rate Low With Peripheral and Nontunneled CVCs Nontunneled Catheters
Virtual Shared Specimen Resource ‘Essential’
DHA Conjugate Increases Paclitaxel Uptake by Tumor Cells
Letrozole Superior to Tamoxifen in Metastatic Breast Cancer
S-8184 Paclitaxel Emulsion Promising in Phase I Study
HIV+ Veterans Have Higher Rates of Unusual Cancers
A Clinician’s Perspective on ASCO 2001: Going After the Epidermal Growth Factor Receptor
Online Breast Cancer Support Groups Beneficial
Survival Benefit With Capecitabine/Docetaxel
FDA Approves Zometa for Cancer-Related Bone Complications
New Blood Test for Early Ovarian Cancer in Clinical Trials
Race Per Se Does Not Predict Extracapsular Prostate Cancer
HIV-Related Lymphoma Differs in Those With Early vs Advanced HIV Infection
Equal Access Erases Racial Disparity in Prostate Cancer Stage
FDA Approves Zevalin for Use With Rituxan in Refractory NHL Patients
Related Videos
Experts on multiple myeloma
Experts on multiple myeloma
Expert on MM
Experts on multiple myeloma
Experts on multiple myeloma
Experts on multiple myeloma
For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.
Expert on MM
Related Content

Personalized Therapy Options Are on the Horizon in Multiple Myeloma

May 20th 2023

Oncology On-The-Go Podcast: Multiple Myeloma Outcome Disparities, Trial Access

April 12th 2023

Review of Emerging Therapies Forecasts A ‘Bright’ Future in Multiple Myeloma

May 13th 2023

Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

May 23rd 2022

Emerging Strategies to Manage Relapsed and/or Refractory Multiple Myeloma

April 29th 2023

The Management of Relapsed and Refractory Multiple Myeloma

April 26th 2023

Personalized Therapy Options Are on the Horizon in Multiple Myeloma

May 20th 2023

Oncology On-The-Go Podcast: Multiple Myeloma Outcome Disparities, Trial Access

April 12th 2023

Review of Emerging Therapies Forecasts A ‘Bright’ Future in Multiple Myeloma

May 13th 2023

Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

May 23rd 2022

Emerging Strategies to Manage Relapsed and/or Refractory Multiple Myeloma

April 29th 2023

The Management of Relapsed and Refractory Multiple Myeloma

April 26th 2023

Personalized Therapy Options Are on the Horizon in Multiple Myeloma

May 20th 2023

Oncology On-The-Go Podcast: Multiple Myeloma Outcome Disparities, Trial Access

April 12th 2023

Review of Emerging Therapies Forecasts A ‘Bright’ Future in Multiple Myeloma

May 13th 2023

Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

May 23rd 2022

Emerging Strategies to Manage Relapsed and/or Refractory Multiple Myeloma

April 29th 2023

The Management of Relapsed and Refractory Multiple Myeloma

April 26th 2023
Related Content

Personalized Therapy Options Are on the Horizon in Multiple Myeloma | Image Credit: © LASZLO - stock.adobe.com.

Personalized Therapy Options Are on the Horizon in Multiple Myeloma

May 20th 2023
Article

Ashley E. Rosko, MD, reviews unmet needs and treatment sequencing for patients with multiple myeloma.


Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.

Oncology On-The-Go Podcast: Multiple Myeloma Outcome Disparities, Trial Access

April 12th 2023
Podcast

Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.


C. Ola Landgren, MD, recaps a recent panel discussion of the rapidly changing treatment landscape in multiple myeloma, and prospects for future development.

Review of Emerging Therapies Forecasts A ‘Bright’ Future in Multiple Myeloma

May 13th 2023
Article

C. Ola Landgren, MD, recaps a recent panel discussion of the rapidly changing treatment landscape in multiple myeloma, and prospects for future development.


Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.

Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

May 23rd 2022
Podcast

Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.


Emerging Strategies to Manage Relapsed and/or Refractory Multiple Myeloma

Emerging Strategies to Manage Relapsed and/or Refractory Multiple Myeloma

April 29th 2023
Article

James J. Driscoll, MD, PhD, and James Ignatz-Hoover, MD, PhD, share a perspective on a study published recently in ONCOLOGY.


The Management of Relapsed and Refractory Multiple Myeloma

The Management of Relapsed and Refractory Multiple Myeloma

April 26th 2023
Article

Zhubin J. Gahvari, MD, MS, and Natalie S. Callander, MD, provide a comprehensive overview of current treatment paradigms in relapsed and refractory multiple myeloma.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.